Background: In recent years, a small but increasing number of neurologists choose to extend dose intervals of natalizumab with the aim of reducing the risk of progressive multifocal leukoencephalopathy (PML). This idea is based on the hypothesis that high drug concentrations increase the risk of PML.
Objective: We investigated the relation between longitudinal natalizumab concentrations in patients who developed PML and patients who did not develop PML.
Methods: In a prospective observational cohort study of 219 patients with relapsing-remitting multiple sclerosis treated with natalizumab, serum samples were taken every 12 weeks prior to natalizumab infusion. In this cohort, 5 patients developed PML and were matched with 10 patients from the cohort who did not develop PML. Natalizumab concentrations were measured in available samples, and the longitudinal results were compared between the two patient groups.
Results: Mean natalizumab concentrations in the five patients developing PML was 18.9 µg/mL (standard deviation (SD): ±13.4) versus 23.8 µg/mL (SD: ±11.5) of the control patients. Furthermore, we did not observe a clear rise in concentration levels in patients subsequently developing PML.
Conclusion: Our results provide preliminary evidence that contradicts the hypothesis that exposure to elevated concentrations of natalizumab is a relevant risk factor of developing PML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1352458516684023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
December 2024
From the Rocky Mountain MS Clinic (J.F.F.), Salt Lake City, UT; Department of Neurology (G.D.), Centre Hospitalier Universitaire de Caen, France; Hackensack Meridian Medical Group - Neurology (L.Z.R.), Jersey Shore University Medical Center, Neptune City, NJ; Mellen MS Center (J.A.C.), Neurological Institute, Cleveland Clinic, OH; Montréal Neurological Institute (D.L.A.), McGill University; NeuroRx Research (D.L.A.), Montréal, Quebec, Canada; Department of Neuroscience (H.B.), Central Clinical School, Monash University, Melbourne, Victoria, Australia; University of Alabama at Birmingham (G.R.C.), School of Public Health; Blizard Institute (G.G.), Barts and The London School of Medicine and Dentistry; Queen Mary University of London (G.G.), United Kingdom; Department of Neurology (J.K.), Amsterdam University Medical Centers, Vrije Universiteit, Netherlands; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Biogen (K.L., L.D., M.T., K.F., J.S., T.L.), Cambridge, MA; and Ashfield MedComms (H.E.), Middletown, CT.
Article Synopsis
- * Results from the NOVA clinical trial show that while patients on Q6W dosing had lower levels of natalizumab compared to Q4W dosing, they still maintained significant clinical efficacy with most patients experiencing stable disease markers over 72 weeks.
- * Key findings included a 23.6% increase in soluble vascular cell adhesion molecule-1 (sVCAM-1) levels in the Q6W
Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.
Mult Scler Relat Disord
October 2024
Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology Outpatient Clinic, De Boelelaan 1118, Amsterdam 1081 HV, the Netherlands.
Background: Several studies reported lower drug concentrations with subcutaneous natalizumab compared to intravenous natalizumab. With the emergence of extended interval dosing, gaining more insight into lower concentrations after subcutaneous administration is essential.
Methods: We compared serum trough concentrations between subcutaneous and intravenous administration within a matched cohort (n = 50).
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
J Neurol Sci
July 2024
MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. Electronic address:
Background And Objectives: Wearing-off symptoms during natalizumab treatment in multiple sclerosis are characterized by an increase of MS-related symptoms prior to natalizumab administration. The influence of extended interval dosing (EID) on wearing-off symptoms are important to consider, as this might cause hesitancy in initiating or continuing EID.
Methods: Participants of the NEXT-MS trial, in which treatment intervals are adjusted based on drug concentrations, were divided into two groups: an extended group containing participants with at least one week of additional interval extension, and a group with a fixed interval during the trial (range 4-7 weeks).
Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration.
Mult Scler Relat Disord
July 2024
Abreos Biosciences, 3550 General Atomics Court(,) G02/rm140, San Diego, CA, USA.
Background: Natalizumab (NAT) pharmacokinetics and pharmacodynamics are complicated by arm exchange with endogenous IgG4, resulting in a mixture of a more potent intact, bivalent form and a less potent, functionally monovalent form. Total NAT and endogenous IgG4 concentrations vary considerably across patients. This study assessed the concentration of intact NAT, and how it relates to total NAT and endogenous IgG4 levels in blood and saliva.
View Article and Find Full Text PDFPharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review.
Clin Pharmacokinet
May 2024
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen and University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Article Synopsis
- A systematic literature review assessed the pharmacokinetics (PK) of monoclonal antibodies (mAbs) used during pregnancy, given the limited existing information on this topic.
- A total of 42 articles were reviewed, focusing mostly on mAbs like infliximab and adalimumab, with findings indicating that serum concentrations for most mAbs either remained stable or slightly decreased during pregnancy, while infliximab showed an increase in the second and third trimesters.
- The study concluded that pregnancy-induced changes in the body could significantly impact mAb behavior, suggesting that higher doses may be necessary for most mAbs to maintain effective serum levels during pregnancy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!